ReviewMedical molecular morphology2011
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Review in Medical molecular morphology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticlesOncology letters · 2017Article
- Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2014Article
- Involvement of DNA damage response pathways in hepatocellular carcinoma.BioMed research international · 2014Review
- Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.Hepatology international · 2014Article
- Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.Medical molecular morphology · 2013Review
- p27 Is a critical prognostic biomarker in non-alcoholic steatohepatitis-related hepatocellular carcinoma.International journal of molecular sciences · 2013Article
- Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma.World journal of gastroenterology · 2013Review
- DNA damage sensor γ -H2AX is increased in preneoplastic lesions of hepatocellular carcinoma.TheScientificWorldJournal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) has an aggressive clinical course with frequent recurrence and metastasis. Orthotopic liver transplantation has been the only curative tool for unresectable HCC; therefore, recent advances in molecular targeted therapy may improve the prognosis of HCC. The multiple kinase inhibitor sorafenib and the macrolide antibiotic rapamycin are currently the most promising agents for treating unresectable HCC. A large population-based clinical trial revealed that sorafenib significantly prolonged the overall survival of HCC patients. However, subsequent clinical studies showed that sorafenib rarely reduced tumor volume and inadequately prolonged survival of patients with severe liver damage. To improve its therapeutic effect, the development of a predictive biomarker and a sorafenib-based combination is awaited. Another molecular targeting agent, rapamycin, has now been considered as a putative agent for preventing tumor recurrence in post-liver transplantation HCC patients, because it not only has immunosuppressive activity but also exerts an anti-tumor effect. In the near future, a combination of molecular targeting agents, such as sorafenib and rapamycin, may become a standard protocol for treating unresectable HCC. For specifying cases with more effective and less harmful modalities, further investigation in clinical and basic research to identify unexpected effects are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.